Literature DB >> 16452242

An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.

Kenji Chamoto1, Daiko Wakita, Yoshinori Narita, Yue Zhang, Daisuke Noguchi, Hideaki Ohnishi, Takeshi Iguchi, Tomoaki Sakai, Hiroaki Ikeda, Takashi Nishimura.   

Abstract

Prior studies have shown that transfer of ovalbumin (OVA)-specific T helper type 1 (Th1) cells into mice bearing MHC class II+ OVA-expressing tumor cells (A20-OVA) causes complete tumor rejection. Here we show that, although Th1 cell therapy alone was not effective against MHC class II- OVA-expressing tumor cells (EG-7), treatment of mice bearing established EG-7 tumors by i.v. transfer of Th1 cells combined with i.t. injection of the model tumor antigen OVA induced complete tumor rejection. Transferred Th1 cells enhanced the migration of tumor-infiltrating antigen-presenting cells (APC) that had processed OVA into the draining lymph node (DLN). Although transferred Th1 cells were randomly distributed in DLN, distal LN, spleen, and tumor tissue, active proliferation of Th1 cells always initiated in DLN, where Th1 cells efficiently interacted with APC that presented OVA. In parallel, OVA-tetramer+ CTLs, showing EG-7-specific cytotoxicity, were highly induced in DLN and the local tumor site. The OVA-tetramer+ CTL functioned systemically because two bilateral tumor masses were both completely rejected on treatment of one tumor. Furthermore, either active proliferation of transferred Th1 cells or generation of tetramer+ CTL was not induced in MHC class II-deficient mice and LN-deficient Aly/Aly mice. These results indicate that DLN is an indispensable organ for initiating active APC/Th1 cell interactions, which is critical for inducing complete eradication of tumor mass by tumor-specific CTL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452242     DOI: 10.1158/0008-5472.CAN-05-2246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade.

Authors:  Yaping Guan; Dongfeng Feng; Beibei Yin; Kun Li; Jun Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-06       Impact factor: 5.485

2.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

3.  Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.

Authors:  Zuqiang Liu; Shenghe Tian; Louis D Falo; Shimon Sakaguchi; Zhaoyang You
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

Review 4.  Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.

Authors:  Zhi-Chun Ding; Gang Zhou
Journal:  Clin Dev Immunol       Date:  2012-02-06

Review 5.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

Review 6.  Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.

Authors:  Emily F Goode; Evanthia T Roussos Torres; Sheeba Irshad
Journal:  Front Mol Biosci       Date:  2021-05-24

7.  Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.

Authors:  T Ohkuri; D Wakita; K Chamoto; Y Togashi; H Kitamura; T Nishimura
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

8.  TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.

Authors:  Shih-Chia Huang; Pei-Chi Wei; Wendy W Hwang-Verslues; Wen-Hung Kuo; Yung-Ming Jeng; Chun-Mei Hu; Jin-Yuh Shew; Chiun-Sheng Huang; King-Jen Chang; Eva Y-Hp Lee; Wen-Hwa Lee
Journal:  EMBO Mol Med       Date:  2017-12       Impact factor: 12.137

Review 9.  Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review.

Authors:  Caressa Hui; Brittney Chau; Greg Gan; William Stokes; Sana D Karam; Arya Amini
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma.

Authors:  Wen-Yu Zhai; Fang-Fang Duan; Si Chen; Jun-Ye Wang; Yao-Bin Lin; Yi-Zhi Wang; Bing-Yu Rao; Ze-Rui Zhao; Hao Long
Journal:  Front Genet       Date:  2022-01-05       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.